Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: Provided herein are methods of detecting pathogen antibodies, such as a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in samples. Related devices, kits, reaction mixtures, and systems are also provided.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: This document relates to methods and materials for targeted expansion of immune effector (Eff) T cells. For example, a composition containing one or more amino acid chains (e.g., one or more single-chain antibody/cytokine fusion proteins (immunocytokines)) that can bind to a heterodimeric receptor including an interleukin-2 receptor-? (IL-2R?) polypeptide and a common gamma chain (?c) polypeptide (e.g., an IL-2R?/?c polypeptide complex) can be administered to a mammal to stimulate Effs within the mammal to activate an immune response in that mammal. In some cases, methods and materials that can be used to treat a mammal having a condition that can benefit from activating an immune response (e.g., a cancer and/or an infectious disease) are provided. For example, a composition containing one or more single-chain immunocytokines that can bind to an IL-2R?/?c polypeptide complex can be administered to a mammal having a cancer and/or an infectious disease to treat the mammal.

Abstract: Provided herein are novel bispecific binding agents and methods of constructing and expressing the same. The methods of constructing the bispecific binding agent generally describes a combination of a knobs-in-holes assembly strategy and a single-chain Fab expression approach to generate a modular bispecific binding platform.

Abstract: The present disclosure relates to bispecific binding agents with a novel format that bind IL-6R? and IL-8R. The present disclosure also relates to methods of using such bispecific binding agents in the treatment of cancer.

Abstract: This document relates to methods and materials for targeted expansion of regulatory T cells (TRegS). For example, one or more single-chain antibody/cytokine fusion proteins (immunocytokines) that can bind to a heterotrimeric receptor including an interleukin-2 receptor-?(IL-2R?) polypeptide, an interleukin-2 receptor-?(IL-2R?) polypeptide, and a common gamma chain (?c) polypeptide (e.g., an IL-2R?/IL-2R?/?c polypeptide complex) can be administered to a mammal to stimulate TRegS within the mammal to reduce or eliminate an immune response in that mammal. In some cases, methods and materials that can be used to treat a mammal having a condition that can benefit from reducing or eliminating an immune response within the mammal are provided. For example, one or more single-chain immunocytokines that can bind to an IL-2R?/IL-2R?/?c polypeptide complex can be administered to a mammal having a condition that can benefit from reducing or eliminating an immune response to treat the mammal.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?cheterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: The disclosure is directed to a biodegradable particle comprising a polyester or polyester blend, a first protein that binds to an immune cell, and a second protein that promotes proliferation and/or activation of immune cells, and a third soluble protein or small molecule encapsulated within the particle. The second protein is a fusion protein comprising at least a portion of an antibody and at least a portion of a cytokine (i.e., an immunocytokine). The disclosure also is directed to methods for treating a disease or condition in a subject (e.g., an autoimmune disease) comprising administering the aforementioned biodegradable particle to the subject.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??cheterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??cheterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??c heterodimer (IL-2R??c), IL-4 receptor ??c heterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.

Abstract: De novo designed polypeptides that bind to IL-2 receptor ??cheterodimer (IL-2R??c), IL-4 receptor ??cheterodimer (IL-4R??c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.